Storia in 3 fonti

Life-prolonging drug for advanced ovarian cancer gets go-ahead in England

Elahere is first new drug for chemotherapy-resistant ovarian cancer to be approved by NHS for 20 years

Raccontata da

independent.co.uk

theguardian.com

dailymail.com

Confronto fonti

3 prospettive sulla stessa storia

AI · summaries

theguardian.comStai leggendo3 mesi fa

Life-prolonging drug for advanced ovarian cancer gets go-ahead in England

Elahere is first new drug for chemotherapy-resistant ovarian cancer to be approved by NHS for 20 years

originale

independent.co.uk3 mesi fa

‘Landmark’ ovarian cancer treatment approved for NHS use

Stay up to date with notifications from The IndependentNotifications can be managed in browser preferences.Jump to contentThank you for registeringPlease refresh the page or navigate to another page on the site to be…

Leggi questa versione → originale

Timeline cronologica

giovedì 4 giugno 2026·independent.co.uk
Hundreds of women to benefit from breakthrough ovarian cancer treatment in UK
Experts have hailed the ‘landmark’ decision from the National Institute for Health and Care Excellence to approve the treatment for NHS use
giovedì 4 giugno 2026·theguardian.com
Life-prolonging drug for advanced ovarian cancer gets go-ahead in England
Elahere is first new drug for chemotherapy-resistant ovarian cancer to be approved by NHS for 20 years

Life-prolonging drug for advanced ovarian cancer gets go-ahead in England

Confronto fonti

Life-prolonging drug for advanced ovarian cancer gets go-ahead in England

‘Landmark’ ovarian cancer treatment approved for NHS use

Timeline cronologica

Hundreds of women to benefit from breakthrough ovarian cancer treatment in UK

Life-prolonging drug for advanced ovarian cancer gets go-ahead in England

Hope for ovarian cancer patients as new drug rolled out on NHS

Hope for ovarian cancer patients as new drug rolled out on NHS

‘Landmark’ ovarian cancer treatment approved for NHS use